Piper Jaffray Remains Neutral On Johnson & Johnson

According to Piper Jaffray, Johnson & Johnson JNJ Neutral rating is maintained. Piper Jaffray said that, after a long wait, the approval of Xarelto for the prevention of DVT following knee and hip replacement comes as a bit of a relief, two years after an FDA panel recommended approval. “We remain Neutral on JNJ primarily due to the company's consent decree with the FDA regarding the OTC business, and the risk that it could potentially widen over the next 12-24 months.” Johnson & Johnson closed on Friday at $67.30.